Success Metrics

Clinical Success Rate
90.3%

Based on 204 completed trials

Completion Rate
90%(204/226)
Active Trials
21(7%)
Results Posted
35%(72 trials)
Terminated
22(8%)

Phase Distribution

Ph phase_1
22
8%
Ph early_phase_1
2
1%
Ph phase_2
46
16%
Ph phase_3
80
28%
Ph phase_4
90
32%
Ph not_applicable
34
12%

Phase Distribution

24

Early Stage

46

Mid Stage

170

Late Stage

Phase Distribution274 total trials
Early Phase 1First-in-human
2(0.7%)
Phase 1Safety & dosage
22(8.0%)
Phase 2Efficacy & side effects
46(16.8%)
Phase 3Large-scale testing
80(29.2%)
Phase 4Post-market surveillance
90(32.8%)
N/ANon-phased studies
34(12.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

86.4%

204 of 236 finished

Non-Completion Rate

13.6%

32 ended early

Currently Active

21

trials recruiting

Total Trials

284

all time

Status Distribution
Active(25)
Completed(204)
Terminated(32)
Other(23)

Detailed Status

Completed204
unknown22
Terminated22
Recruiting19
Withdrawn10
Not yet recruiting3

Development Timeline

Analytics

Development Status

Total Trials
284
Active
21
Success Rate
90.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (0.7%)
Phase 122 (8.0%)
Phase 246 (16.8%)
Phase 380 (29.2%)
Phase 490 (32.8%)
N/A34 (12.4%)

Trials by Status

enrolling_by_invitation10%
recruiting197%
completed20472%
suspended10%
not_yet_recruiting31%
unknown228%
active_not_recruiting21%
terminated228%
withdrawn104%

Recent Activity

Clinical Trials (284)

Showing 20 of 284 trialsScroll for more
NCT05303064Phase 3

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

Recruiting
NCT06200181Phase 3

Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial

Recruiting
NCT07565428Phase 3

Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

Recruiting
NCT00044655Phase 4

Switching Medication to Treat Schizophrenia

Completed
NCT07581405Phase 2

GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer

Not Yet Recruiting
NCT06554613Phase 2

Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC

Recruiting
NCT07482891Phase 4

An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC

Recruiting
NCT07208305Phase 3

Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting

Recruiting
NCT04478838Phase 4

"Extended" (Alternate Day) Antipsychotic Dosing

Recruiting
NCT04939090Phase 3

Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

Active Not Recruiting
NCT06331520Phase 3

NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens

Completed
NCT07442890Not Applicable

A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Rolapitant and Palonosetron

Not Yet Recruiting
NCT06995508Phase 2

Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial

Recruiting
NCT07413809Phase 3

Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen

Recruiting
NCT00183625Phase 4

Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients

Completed
NCT05669742Phase 3

Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients

Recruiting
NCT05814640Phase 1

Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)

Recruiting
NCT04216329Phase 1

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

Active Not Recruiting
NCT05705492Phase 2

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

Recruiting
NCT05676294Phase 2

The Impact of Preoperative Olanzapine on Quality of Recovery After Discharge From Ambulatory Surgery

Completed

Drug Details

Intervention Type
DRUG
Total Trials
284